N-carbamimidoyl-3-(2-((E)-3-(diaminomethyleneamino)-2-methyl-3-oxoprop-1-enyl)-4-methylphenyl)-2-methylacrylamide

ID: ALA3897683

Chembl Id: CHEMBL3897683

PubChem CID: 10065980

Max Phase: Preclinical

Molecular Formula: C17H22N6O2

Molecular Weight: 342.40

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C/C(=C\c1cc(C)ccc1/C=C(\C)C(=O)NC(=N)N)C(=O)N=C(N)N

Standard InChI:  InChI=1S/C17H22N6O2/c1-9-4-5-12(7-10(2)14(24)22-16(18)19)13(6-9)8-11(3)15(25)23-17(20)21/h4-8H,1-3H3,(H4,18,19,22,24)(H4,20,21,23,25)/b10-7+,11-8+

Standard InChI Key:  UEWGFTFNXDMBAM-AMMQDNIMSA-N

Associated Targets(Human)

SLC9A1 Tchem Sodium/hydrogen exchanger 1 (412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC9A3 Tclin Sodium/hydrogen exchanger 3 (483 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

SLC9A2 Sodium/hydrogen exchanger 2 (9 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 342.40Molecular Weight (Monoisotopic): 342.1804AlogP: 0.61#Rotatable Bonds: 4
Polar Surface Area: 160.44Molecular Species: NEUTRALHBA: 3HBD: 5
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 8#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.52CX Basic pKa: 6.96CX LogP: 1.04CX LogD: 0.90
Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.31Np Likeness Score: -0.11

References

1.  (2014)  NHE3-binding compounds and methods for inhibiting phosphate transport, 
2.  (2013)  Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders, 
3.  (2016)  Nhe3-binding compounds and methods for inhibiting phosphate transport, 

Source